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Abstract
Objective
To identify novel genetic associations with white matter hyperintensities (WMH).
Methods
We performed a genome-wide association meta-analysis of WMH volumes in 11,226 indi-
viduals, including 8,429 population-based individuals from UK Biobank and 2,797 stroke
patients. Replication of novel loci was performed in an independent dataset of 1,202 individuals.
In all studies, WMH were quantiﬁed using validated automated or semi-automated methods.
Imputation was to either the Haplotype Reference Consortium or 1,000 Genomes Phase 3
panels.
Results
We identiﬁed a locus at genome-wide signiﬁcance in an intron of PLEKHG1 (rs275350, β [SE] =
0.071 [0.013]; p = 1.6 × 10−8), a Rho guanine nucleotide exchange factor that is involved in
reorientation of cells in the vascular endothelium. This association was validated in an in-
dependent sample (overall p value, 2.4 × 10−9). The same single nucleotide polymorphism was
associated with all ischemic stroke (odds ratio [OR] [95% conﬁdence interval (CI)] 1.07
[1.03–1.12], p = 0.00051), most strongly with the small vessel subtype (OR [95% CI] 1.09
[1.00–1.19], p = 0.044). Previous associations at 17q25 and 2p16 reached genome-wide signif-
icance in this analysis (rs3744020; β [SE] = 0.106 [0.016]; p = 1.2 × 10−11 and rs7596872; β
[SE] = 0.143 [0.021]; p = 3.4 × 10−12). All identiﬁed associations with WMH to date explained
1.16% of the trait variance in UK Biobank, equivalent to 6.4% of the narrow-sense heritability.
Conclusions
Genetic variation in PLEKHG1 is associated with WMH and ischemic stroke, most strongly
with the small vessel subtype, suggesting it acts by promoting small vessel arteriopathy.
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Cerebral white matter hyperintensities (WMH) are a radio-
logic marker of cerebral small vessel disease (SVD), the major
cause of vascular dementia, and the pathology underlying
both subcortical lacunar ischemic strokes and deep in-
tracerebral hemorrhages (ICH), which together constitute
a signiﬁcant proportion of stroke. Furthermore, WMH are
associated with both stroke and dementia risk in the general
population.1 Despite the clinical importance of WMH, their
pathogenesis is incompletely understood. Vascular risk fac-
tors, such as elevated blood pressure and diabetes mellitus, are
thought to be important and management of these factors is
currently the only treatment for SVD.
Identifying new treatments for SVD is constrained by our
limited understanding of the underlying disease. Genetic
studies are one of the few ways of identifying genuinely new
pathways leading to disease and therefore hold promise to
discover new potential treatments. Twin studies have dem-
onstrated a high heritability for WMH,2,3 suggesting genetic
factors are likely to confer considerable disease risk. Previous
genome-wide association studies (GWAS) have uncovered
a number of loci that inﬂuence WMH,4,5 and these in com-
bination have been shown in turn to increase risk of lacunar
stroke.6 However, these variants explain only a fraction of
disease risk, motivating further identiﬁcation of WMH-
associated loci.
In this analysis, we performed a GWAS of WMH in 11,226
individuals to identify novel genetic variants associated
with WMH.
Methods
Study populations and ethical approval
Two study populations were combined in a meta-analysis to
examine the genetic basis of WMH: UK Biobank and the
WMH in Stroke Study. A third population was used for
replication: the Massachusetts General Hospital (MGH)
WMH Study.
UK Biobank (ukbiobank.ac.uk) is a prospective study that
recruited 500,000 community-dwelling participants aged
40–69 years from across the United Kingdom between 2006
and 2010. The study collects extensive data from ques-
tionnaires, interviews, health records, physical measures, bi-
ological samples, and imaging.
A subset of UK Biobank participants also underwent MRI of
the head.7 This study used the second release of MRI data,
including 9,045 participants who underwent brain MRI, on
average 6.6 years (SD 1.0 years) after initial recruitment at
mean age 55.5 years (SD 7.4 years) and had usable T2 ﬂuid-
attenuated inversion recovery (FLAIR) or diﬀusion tensor
imaging images. We excluded participants with a diagnosis of
stroke (ICD-9/ICD-10 or self-report or health record linkage),
multiple sclerosis, Parkinson disease, dementia, or any other
neurodegenerative disease at baseline, as well as participants
with no genetic data. Following visual inspection of the data by
the authors, 3 further participants with outlying tract-averaged
water diﬀusion biomarker values were removed.
The WMH in Stroke Study data have been described pre-
viously.5 Ischemic stroke populations were enrolled between
1995 and 2013 through hospital-based studies. Further data
are available fromOpen Science Framework (table e-1, osf.io/
pkruv). We excluded from analyses patients with cerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL) or any other sus-
pected monogenic cause of stroke, vasculitis, or any other
nonischemic cause of WMH such as demyelinating and mi-
tochondrial disorders.
Data were derived from contributing studies of the Wellcome
Trust Case Control Consortium 2 (WTCCC2) (Oxford,
Edinburgh, Munich, and St. George’s, University of London
[SGUL]), as well as other hospital-based cohorts: Milano
Besta, Genes and Ischaemic Stroke (GENESIS), Leuven
Stroke Study, South London Ethnicity and Stroke Study
(SLESS), and DNA Lacunar.
The MGH WMH Study data have been described pre-
viously.5 MRI scans were derived from MGH, Ischemic
Stroke Genetics Study, Australian Stroke Genetics Collabo-
rative studies, and the Siblings with Ischemic Stroke Study.
Glossary
BIANCA = Brain Intensity Abnormality Classiﬁcation Algorithm; CADASIL = cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy; CI = conﬁdence interval; FLAIR = ﬂuid-attenuated inversion recovery; GC =
genomic control; GENESIS = Genes and Ischaemic Stroke; GWAS = genome-wide association studies; HRC = Haplotype
Reference Consortium; ICA = intracranial area; ICD-9 = International Classiﬁcation of Diseases–9; ICD-10 = International
Classiﬁcation of Diseases–10; ICH = intracerebral hemorrhage; MGH = Massachusetts General Hospital; OR = odds ratio;
PLEKHG1 = pleckstrin homology and Rho guanine nucleotide exchange factor domain containing G1; Rho-GEF = Rho
guanine nucleotide exchange factor; ROI = region of interest; SGUL = St. George’s, University of London; SLESS = South
London Ethnicity and Stroke Study; SNP = single nucleotide polymorphism; SVD = small vessel disease; TI = inversion time;
TICV = total intracranial volume; TR = repetition time;WMH = white matter hyperintensities;WTCCC2 = Wellcome Trust
Case Control Consortium 2.
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Genotype data
The UK Biobank genotyping procedure has been described
elsewhere.8 In short, 2 custom genotyping arrays were used to
genotype 49,950 participants (UK BiLEVE Axiom Array) and
438,427 participants (UK Biobank Axiom Array).8,9 Geno-
type data (805,426 markers) were available for 488,377
individuals, and were subsequently imputed to the Haplotype
Reference Consortium (HRC) reference panel (39,131,578
autosomal single nucleotide polymorphisms [SNPs]). Im-
puted genotypes were available for 487,442 individuals in this
study.8 From the resulting imputed dataset, we excluded (1)
individuals who did not segregate with European individuals
based on principal component analysis, (2) individuals with
high levels of heterozygosity or missingness (>5%), and (3)
individuals whose reported sex did not match with sex infer-
red from the genetic data. Only SNPs imputed from the HRC
panel were included in this analysis.
The WMH in Stroke Study data genotyping has been de-
scribed previously.5 All data were genotyped on commercially
available Illumina arrays. Quality control procedures involved
removing SNPs and individuals with high levels of missing-
ness, discordant phenotypic and genotypic sex, strand am-
biguous SNPs, and deviations from Hardy-Weinberg
equilibrium (p < 1 × 10−6). For this analysis, all datasets were
then imputed to 1,000 Genomes phase 3 (all populations)
using SHAPEIT2 and IMPUTE2.
The MGH WMH Study data genotyping has been described
previously.5 All individuals were genotyped on commercially
available GWAS arrays from Aﬀymetrix (Santa Clara, CA) or
Illumina (San Diego, CA). Standard quality control was
performed on the data, equivalent to the WMH in Stroke
Study, and the datasets were imputed to 1,000 Genomes
phase 1 integrated variant set using SHAPEIT2 and
IMPUTE2.
Standard protocol approvals, registrations,
and patient consents
UK Biobank received ethical approval from the research
ethics committee (reference 11/NW/0382). All participants
provided informed consent to participate. The present anal-
yses were conducted under UK Biobank application number
36509. An institutional review board or regional review board
has approved the use of human participants in each of the
WMH in Stroke study populations. All patients gave informed
consent.
Phenotype derivation
UK Biobank procedures for brain imaging acquisition are
available on the UK Biobank website (Brain Imaging Docu-
mentation V1.3, ukbiobank.ac.uk). Our analyses made use of
imaging-derived phenotypes/preprocessed image data esti-
mated by an image-processing pipeline developed and run on
behalf of UK Biobank.10 In brief, all brain MRI data were
acquired on one standard Siemens Skyra 3T scanner (Sie-
mens Medical Solutions, Munich, Germany) using the
standard Siemens 32-channel RF receiver head coil. T1-
weighted sagittal scans were acquired using a 3D
magnetization-prepared rapid acquisition gradient echo se-
quence (resolution 1 × 1 × 1 mm, ﬁeld of view 208 × 256 ×
256, inversion time [TI]/repetition time [TR] = 880/2,000
ms). T2-weighted FLAIR sagittal scans were obtained using
a 3D SPACE sequence (resolution 1.05 × 1.0 × 1.0 mm, ﬁeld
of view 192 × 256 × 256, TI/TR = 1,800/5,000 ms). Details of
quality control procedures for the MRI data and image pro-
cessing are freely available on the UK Biobank website (Brain
Imaging Documentation V1.3, ukbiobank.ac.uk) and have
been previously described. WMH were segmented automat-
ically using the combined T1 and T2 FLAIR data as input in
the Brain Intensity Abnormality Classiﬁcation Algorithm
(BIANCA) tool.11 BIANCA is a fully automated supervised
method for WMH detection that gives the probability per
voxel of beingWMHbased on a k-nearest neighbor algorithm.
The total WMH volume was calculated from the voxels within
a white matter mask exceeding a probability of 0.9 of being
WMH. Subsequent values were corrected for natural head size
based on the total intracranial volume and natural log trans-
formed due to their skewed distribution.
In the WMH in Stroke Study data, we largely employed the
same methodology as in our previous analysis.5 MRI scans
were acquired as part of routine clinical practice for evalu-
ation of ischemic stroke. FLAIR sequences were primarily
used for WMH volumetric analysis; however, in their ab-
sence, T2-weighted sequences were used (WTCCC2-
Oxford and WTCCC2-Munich only). In all scans, to
avoid confounding by hyperintense signal due to the stroke
for which the patient was enrolled, WMH were assessed in
the contralateral hemisphere to the acute event. Lacunar
infarcts were identiﬁed as low signal on T1 or FLAIR images
using standard criteria and were excluded from WMH
estimates.12 Trained raters blinded to all patient in-
formation outside of the MRI analyzed anonymized MRI
scans. All supratentorial white matter and deep gray matter
lesions were included in WMH volumes with the exception
of WMH corresponding to infarcts, both lacunar and ter-
ritorial.13 MRI scans with excessive movement artefact, in-
complete brain coverage, or bihemispheric infarcts (other
than lacunar) were excluded.
The WTCCC2, GENESIS (1 and 2), SGUL, Leuven, and
Milan cohorts were analyzed using DISPunc, a semi-
automated lesion drawing software.14 A manually marked
“seed” at the lesion border was ﬁrst identiﬁed, and then out-
lined automatically based on the signal intensity gradient.
Visual inspection andmanual correction of eachWMH region
of interest (ROI) was then performed as required. The SLESS
and GENESIS 3 datasets were analyzed separately. WMH
were deﬁned as areas of increased signal on FLAIR images and
segmented using a semi-automated contouring technique in
Jim image analysis software version 7.0 5 (Xinapse Systems
Limited; xinapse.com/j-im-7-software/) and corrected as
necessary. To estimate total intracranial volume (TICV) in all
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WMH in Stroke Study datasets, T2-weighted and, in their
absence, FLAIR sequences were analyzed using an automated
segmentation program: SIENAX, part of FSL,15 which cal-
culates the total volume of CSF and gray and white matter
volumes. For all participants, WMH volumes were doubled to
obtain a whole brain estimate and then corrected for TICV,
thereby correcting for natural diﬀerences in head size. The
values were subsequently natural log transformed.
For the MGHWMH Study, the protocol matched that of the
WMH in Stroke Study above. FLAIR sequences were ana-
lyzed using a semi-automated method using MRIcro as pre-
viously described.13 Overlapping ROIs corresponding to
WMH were marked to produce the ﬁnal maps for WMH
volume calculation. Intracranial area (ICA) was derived as the
average of 2 midsagittal slices traced based on anatomical
landmarks on T1 sequences, and used to correct for natural
diﬀerences in head size.16 The phenotype for analysis was
derived as above.
Genome-wide analysis, meta-analysis,
and replication
The UK Biobank and WMH in Stroke Study populations
were analyzed separately and then combined in a meta-
analysis.
In UK Biobank, we performed a GWAS of log (WMH), using
SNPTEST v2.5.4-beta3. We included age at MRI, sex, geno-
typing batch, and the ﬁrst 10 ancestry informative principal
components as covariates. Data contributing to the WMH in
Stroke datasets were analyzed using plink v1.90b3.45, in-
cluding age at MRI, sex, and ancestry informative principal
components as covariates.
Before performing a meta-analysis, we evaluated the degree of
genetic correlation between the 2 datasets using
LDSCORE.17 After conﬁrming high genetic correlation, we
performed a joint analysis of the datasets, meta-analyzing
using metal.18 SNPs with p values for association with WMH
less than 5 × 10−8 were considered signiﬁcant.
For SNPs reaching p < 5 × 10−8, we sought replication in the
MGH WMH Study. We evaluated the overall evidence for
association by performing an inverse variance weighted meta-
analysis.
All studies corrected for either intracranial volume or ICA in
derivation of the phenotype (see above) to correct for natural
diﬀerences in head size.
Genomic control (GC) correction was applied to all in-
dividual studies.19 Our primary analysis did not include GC
correction of the overall meta-analysis (double-GC correc-
tion) as this is considered conservative.17,20 However, for
completeness, we did perform a secondary double-GC cor-
rection of meta-analysis p values, which we include in the
Results.
Fine-mapping derived from credible SNP
set analyses
We calculated credible SNP sets for loci associated with
WMH at genome-wide signiﬁcance to identify the set of SNPs
that contain the causal SNP with 95% certainty. We calculated
Bayes factors from the eﬀect sizes and standard errors using
Wakeﬁeld21 approximation for all SNPs in linkage disequi-
librium (r2 > 0.1) with the lead SNP. Based on these Bayes
factors, we calculated the posterior probability that each
speciﬁc variant is causal, as well as the 95% credible set for
each association (the smallest set of variants with posteriors
that sum to at least 95%).22
Association of PLEKHG1 SNP with related
neurologic and cardiovascular traits
For a novel SNP (rs275350) associated with WMH, we ex-
amined associations with related neurologic and cardiovas-
cular traits, namely ischemic stroke and its subtypes;
cardioembolic, large vessel, and small vessel stroke23; ICH
(including subtypes by location: deep and lobar)24; coronary
artery disease25; and Alzheimer disease.26 We note that
rs275350 did not pass quality control in the ICH datasets, so
a close proxy SNP (rs12202497, r2 = 0.93) was used in its
place. Further data are available from Open Science Frame-
work (table e-2; osf.io/pkruv).
Bioinformatics analyses of a PLEKHG1 locus
using publicly available databases
To identify the putative function of a novel locus, we in-
terrogated a variety of online resources. We identiﬁed the
tissue-speciﬁc expression pattern of the gene in which the
novel SNP resides using GTEx portal (gtexportal.org).27
Using the same resource, we tested whether the lead SNP was
associated with expression of the same gene in brain, vascular,
and blood tissues. We used the Capture HiC Plotter (chicp.
org/), which interrogates data pertaining to interactions be-
tween distant DNA elements and enhancer and promoter
sites of genes, to assess interactions between our PLEKHG1
locus and genome-wide genes.28,29 We used the International
Mouse Phenotyping Consortium data (mousephenotype.
org/) to evaluate the phenotype of mice with PLEKHG1
knocked out.30 We used PhenoScanner (phenoscanner.
medschl.cam.ac.uk/phenoscanner) to identify any published
associations between the PLEKHG1 variant and proxies (r2 >
0.6) and any GWAS, eQTL, or metabolite phenotype.31
Data availability
Full summary statistics from the meta-analysis are available to
download from the Cerebrovascular Portal (cere-
brovascularportal.org/informational/downloads).
Results
Genome-wide meta-analysis
After quality control, 8,429 individuals were analyzed in UK
Biobank, and 2,797 in the WMH in Stroke dataset. The ge-
netic correlation between the 2 datasets was very high (rG
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[SE] = 0.93 [0.68]), indicating high sharing of genetic
mechanisms between the 2 populations, and justifying com-
bining the 2 populations in a meta-analysis. Genomic inﬂation
factors (λ) and LDSCORE intercepts indicated no signiﬁcant
inﬂation in the WMH in stroke (λ = 1.04, intercept = 1.04)
and UK Biobank datasets (λ = 1.05, intercept = 1.01), as well
as for the resulting meta-analyzed dataset (λ = 1.05, intercept
= 1.01).17,19 QQ plots data are available from Open Science
Framework (ﬁgures e-1 to e-4; osf.io/pkruv).
In the genome-wide meta-analysis of the 11,226 participants,
we identiﬁed an association intronic of the PLEKHG1 gene
(rs275350; β [SE] = 0.071 [0.013]; p = 1.6 × 10−8). The SNP
was associated with WMH in both UK Biobank (β [SE] =
0.065 [0.013]; p = 7.9 × 10−7) and in stroke populations (β
[SE] = 0.12 [0.041]; p = 0.0026).We also conﬁrmed 2 previous
associations at genome-wide signiﬁcance: one at 17q25, local-
izing to TRIM47 and TRIM65 (rs3744020; β [SE] = 0.106
[0.016]; p = 1.2 × 10−11), and a second on chromosome 2,
close to EFEMP1 (rs7596872; β [SE] = 0.143 [0.021]; p = 3.4
× 10−12).4,5 For all 3 loci, there was no evidence of heteroge-
neity either within the WMH in Stroke cohorts or between the
WMH in Stroke and UK Biobank datasets (table; forest plots
data available from Open Science Framework [ﬁgures e-5 and
e-6; osf.io/pkruv]). Of the 12 SNPs previously reported as
being associated with WMH,4,5 all had consistent direction of
eﬀect in this analysis, and 9 had p < 0.05 (further data available
from Open Science Framework [table e-2; osf.io/pkruv]). All
13 SNPs associated withWMH at genome-wide signiﬁcance to
date explained 1.16% of the WMH variance in UK Biobank, of
which rs275350 contributed 0.19%. Using LDSCORE, we es-
timated heritability of WMH to be 18.0%, meaning these 13
variants explain 6.4% of the narrow-sense heritability, of which
rs275350 contributed 1.1%.
We sought replication of the PLEKHG1 SNP in a further
1,202 stroke patients from the MGHWMH study. There was
a consistent eﬀect in this population (β [SE] = 0.080 [0.042];
p = 0.057), increasing evidence for association of the SNP
overall (p = 2.5 × 10−9).
Credible sets for the PLEKHG1 locus contained 6 SNPs
(rs275350, rs6940540, rs12192990, rs62434144, rs12202497,
rs6916149); 3 SNPs for the EFEMP1 locus (rs7596872,
rs146896516, rs113481311); and 33 SNPs for the 17q25
locus.
Association of rs275350 with related
neurologic and cardiovascular traits
The PLEKHG1 SNP (rs275350) was associated with all is-
chemic stroke (odds ratio [OR] [95% conﬁdence interval
(CI)] 1.07 [1.03–1.12], p = 0.00051; ﬁgures 1–3), most
strongly with the small vessel subtype (OR [95% CI] 1.09
[1.00–1.19], p = 0.044). The eﬀects for ICH were similar to
small vessel stroke (OR [95% CI] 1.10 [0.99–1.21], p =
0.075), particularly for deep ICH (OR [95% CI] 1.12
[1.00–1.27], p = 0.058), but were nonsigniﬁcant due to larger Ta
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CIs. Conversely, there was no evidence of association with
coronary heart disease or Alzheimer disease.
Bioinformatics analyses of rs275350 using
publicly available databases
PLEKHG1 is widely expressed in many tissues, including
brain and arterial tissues (further data available from Open
Science Framework [ﬁgure e-7]; osf.io/pkruv). Capture Hi-C
data showed interactions between DNA at rs275350 with
promoter sites of PLEKHG1 as well as nearby genes ZBTB2
and PPP1R14C in GM12878 lymphoblastoid cells, suggesting
the variant might inﬂuence expression of these genes. There is
no evidence that PLEKHG1 knockout mice have brain or
cardiovascular defects, but female PLEKHG1 knockout mice
have elevated fructosamine levels (p = 1.2 × 10−7; sex in-
teraction p = 1.0 × 10−4). We used GTEx portal to assess the
relationship between rs275350 and PLEKHG1 mRNA ex-
pression in brain, vascular, and blood tissues. There were
nominally signiﬁcant associations with expression of
PLEKHG1 in brain and vascular tissues (further data available
Figure 1Manhattan plot of genome-wide –log 10 (p values) for association with white matter hyperintensities by genomic
position
Figure 2 Local plot shows –log 10 (p values) for associations with white matter hyperintensities at PLEKHG1 locus
Linkage disequilibrium r2 with lead
single nucleotide polymorphism
(SNP) given in shades of red, or-
ange, and yellow. SNPs with low r2
with the lead SNP (r2 < 0.2) are
shown in gray. CI = confidence in-
terval; OR = odds ratio; PLEKHG1 =
pleckstrinhomologyandRhoguanine
nucleotide exchange factor domain
containing G1; MTHFD1L = methyl-
enetetrahydrofolate dehydrogenase
(NADP+dependent) 1 likegene; RAF=
risk allele frequency.
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from Open Science Framework [table e-4]; osf.io/pkruv),
but none reached Bonferroni-corrected signiﬁcance. A
hypothesis-free search of the GTEx database highlighted an
association with expression of PPP1R14C in esophageal mu-
cosa (p = 1.9 × 10−5). Using PhenoScanner, we identiﬁed no
other associations of rs275350, or proxies with r2 > 0.6, with any
reported GWAS, eQTL, or metabolomic phenotypes.
Discussion
In this genome-wide meta-analysis in 11,226 individuals, we
identiﬁed an association with WMH in an intron of pleckstrin
homology and Rho guanine nucleotide exchange factor (Rho-
GEF) domain containingG1 (PLEKHG1), which we validated
in an independent population. PLEKHG1 belongs to a family
of Rho-GEFs, which activate Rho family small GTPases by
catalyzing the exchange of GDP for GTP. In the vascular
endothelium, Rho-GEFs—including PLEKHG1—are in-
volved in reorientation of cells and their stress ﬁbers in re-
sponse to mechanical stress.32 Disruption of this reorientation
is a potential mechanism by which the identiﬁed variant might
increase WMH burden. Variants in PLEKHG1 have been as-
sociated with blood pressure in African Americans.33,34
However, the SNPs identiﬁed in this study were only weakly
correlated with the blood pressure–associated variants (r2 =
0.057), suggesting the mechanism associated with the variant
identiﬁed in this analysis is likely to be distinct. The SNP was
also associated with all ischemic stroke, an association that was
strongest for the small vessel subtype. Eﬀects were similar for
ICH, particularly subcortical, but were not signiﬁcant. This
association with other stroke phenotypes, particularly small
vessel stroke, might point to the SNP increasing risk by a small
vessel arteriopathy.
We explored whether the SNP in PLEKHG1 is an eQTL,
inﬂuencing expression of nearby genes, particularly PLEKHG1.
There were nominal associations with PLEKHG1 expression in
brain and vascular tissues and an association with PPP1R14C in
tissue presumed not to be disease relevant. Further interrogation
of gene expression associations with genetic variation at the locus
in disease relevant tissue will help to shed light on whether these
are true-positive associations. From the data available, we are not
able to determine which SNP is the causal variant that increases
WMHburden.Novelmethods such asmassively parallel reporter
assaysmay help to shed light on this.35 Furthermore, determining
the biological function of GWAS-associated variants, such as the
PLEKHG1 variants identiﬁed here, remains challenging. How-
ever, notable recent successes have involved CRISPR-editing
stem cell–derived cells,36 and such an approach has appeal for
interrogating cerebral SVD-associated loci. In addition, recall-by-
genotype and phenome-wide association studies, particularly
with detailed MRI variables, have the potential to illuminate the
full phenotypic spectrum of the associated variant.37,38
In addition, we validated 2 previously identiﬁed loci on
chromosomes 2p16 (EFEMP1) and 17q25 (TRIM47/
TRIM65). EFEMP1 is an extracellular matrix glycoprotein,
the gene product of which is ﬁbulin 3. Fibulin 3 has been
shown to have an antagonistic eﬀect on vessel development
and repressive eﬀect on expression of some matrix metal-
loproteinases.39 Perhaps most interestingly, ﬁbulin has been
shown to induce expression of TIMP3, which ameliorates
disease manifestations in CADASIL mice,40 highlighting
shared pathologic processes in sporadic and monogenic small
vessel disease. The 17q25 locus overlaps several genes, in-
cluding 2 tripartite-containing motifs (TRIM47, TRIM65). As
has been reported before,4 several of the genome-wide sig-
niﬁcant SNPs in this locus are missense variants, and many
inﬂuence expression of TRIM47 in brain tissues. We note that
one SNP in the region, rs4600514 (p.Arg187Trp), in an exon
of TRIM47, is predicted as “probably damaging” by Polyphen,
“deleterious” by SIFT, and has a CADD score of 34,41
meaning it is in the top 0.1% of SNPs for likelihood of dele-
teriousness. This might point to knockout of TRIM47 being
the underlying mechanism conferring risk of WMH.
Our study has several strengths. The study had a large sample
size. In UK Biobank, a uniform high-quality image acquisition
protocol was used. Automated or semiautomatic segmenta-
tion methods were used to quantify WMH in all studies,
which have beneﬁts over ratings scale, which can be subject to
ceiling eﬀects. The PLEKHG1 GWAS association we identi-
ﬁed was validated in an independent population, although this
did not quite reach statistical signiﬁcance independently.
However, there are also limitations. At this point, our obser-
vations cannot be generalized to non-European populations.
Only 2% of participants of the UK Biobank imaging substudy
were of non-European ancestry and were therefore excluded
in this analysis. In the WMH in Stroke Study population,
a small subset of scans were T2-weighted rather than FLAIR
images, which can be less accurate for identifying WMH. In
Figure 3 Association of rs275350 with related neurologic
and cardiovascular traits
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addition, methods for lesion and brain volume were diﬀerent
in the 2 groups. In the WMH in stroke population, a number
of raters calculated lesion volumes. Interrater reliability was
high (>0.9) among all individuals, but subtle diﬀerences and
biases could still remain. To maximize sample size in this
analysis, we combined data from community and stroke
populations. We found high genetic correlation between the 2
populations and previous analyses have shown all associated
genetic variants to inﬂuence disease risk in both populations.5
It is possible that including a population selected on the basis
of disease could exert subtle inﬂuences on the estimated eﬀect
of genetic variants. However, there was no evidence of het-
erogeneity between the populations for any of the genome-
wide signiﬁcant variants and eﬀects were observed in both
cohorts. In age-related traits such as WMH, measurement of
the phenotype in an aged population depends on survival of
those individuals to the point of recruitment. Therefore, in
addition, subtle survival biases may inﬂuence the estimated
eﬀect. As with all genome-wide studies, the most accurate
estimate of the eﬀect of a given variant should be obtained
from a large independent population-based cohort.
Genetic variation in PLEKHG1 is associated with WMH, as
well as ischemic stroke and in particular small vessel stroke,
suggesting it confers risk via small vessel arteriopathy.
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